MasterCard Inc vs GeneDx Holdings Corp — how do they compare? MasterCard Inc trades at $556.95 (market cap $491.83B), while GeneDx Holdings Corp trades at $82.5 (market cap $2.44B). The key difference: MasterCard Inc is far larger — about 201.6× GeneDx Holdings Corp's market cap, and MasterCard Inc pays a 0.62% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MA | WGS | |
|---|---|---|
Market Cap | $491.83B | $2.44B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $598.96 | $167.51 |
52-Week Low | $471.55 | $34.51 |
Enterprise Value | $504.86B | $2.48B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $563.17, showing stability with a slight 0.04% daily gain. The stock exhibits strong fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and maintains robust profitability with a 46.34% net income margin. Technical indicators signal a bullish trend, supported by moving averages, while analyst consensus is overwhelmingly positive with a $660.85 price target. Recent news highlights institutional acquisitions and strategic initiatives in AI and digital inclusion.
Outlook remains favorable driven by consistent earnings beats and revenue growth, though risks include competitive pressures from emerging payment technologies like stablecoins and high valuation multiples. The stock presents a growth opportunity with solid institutional backing, but investors should monitor execution on innovation and macroeconomic factors affecting consumer spending.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →